Financial Gravity Asset Management’s Galectin Therapeutics GALT Stock Holding History

Financial Gravity Asset Management’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$7.32K	Buy	+5,997	New	+$8.41K	﹤0.01%	663

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Financial Gravity Asset Management's GALT Position: Q1 2025 in Review

Financial Gravity Asset Management opened a new position in Galectin Therapeutics (GALT) in Q1 2025: 5,997 shares worth $7.32K. The stake represents ﹤0.01% of the portfolio and ranks #663 among its holdings.

93 funds tracked by Wall St. Rank hold GALT as of Q1 2025.

Financial Gravity Asset Management held 5,997 shares of Galectin Therapeutics worth $7.32K as of Q1 2025.
Galectin Therapeutics was a new Financial Gravity Asset Management position in Q1 2025.
Galectin Therapeutics made up ﹤0.01% of Financial Gravity Asset Management's portfolio in Q1 2025, its #663 holding.
93 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2025.

Based on Financial Gravity Asset Management's 13F filing for Q1 2025, filed 30 Apr 2025.